What Setal MR Treats: Main Uses and Benefits

Setal MR is a cytoprotective anti-ischemic agent applied across domains where additional symptomatic support is needed for specific cardiovascular conditions. Its application is generally focused on contributing to improved comfort and functional stability during symptomatic periods. The medicine is primarily indicated for the symptomatic treatment of stable angina pectoris in adults, particularly as add-on therapy when patients are inadequately controlled by or when standard treatments are not suitable.

---

Managing Recurrent Angina Attacks and Chest Pain

The drug is commonly used to help manage symptoms that interfere with daily functioning, such as the recurrent chest discomfort, tightness, and pain associated with myocardial ischemia. For the patient, this means the medicine helps reduce the frequency of these episodic angina attacks and supports tolerance for physical exertion. In such clinical scenarios, the focus is on easing the overall burden of persistent symptoms.

“Supportive relief is provided for individuals with persistent, challenging symptom manifestations.”

Quick Fact: Relief for Angina Pectoris
Main Therapeutic Role: Supportive care for patients with stable angina whose symptoms remain inadequately managed.
Benefit to Function: Contributes to improved comfort and supports functional stability during periods of activity.

Eligibility Map: Who can and cannot use Setal MR — Official Regulatory Information

The eligibility for Setal MR (Trimetazidine Modified-Release) is strictly defined by regulatory documents, prohibiting its use in certain populations and restricting it in others, based on documented patient factors and contraindications.

---

Eligibility Scope

• Populations for whom use is allowed (as stated in label): Adults with stable angina pectoris.
• Populations for whom use is not recommended: Children and adolescents aged below 18 years.
• Populations for whom use is contraindicated: Patients with Hypersensitivity to the drug or excipients; patients with Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders.
• Condition-specific eligibility rules: Severe renal impairment (creatinine clearance < 30 mL/min) is an absolute contraindication.
• Age-related eligibility rules: Caution is required when prescribing to elderly patients (older than 75 years) due to increased drug exposure risks.
• Pregnancy and lactation eligibility status: Use is preferable to avoid during pregnancy, and the medicine should not be used during breastfeeding.

---

Eligibility Classifications (High-Level)

• Eligibility severity classification (as defined in official documents): Contraindicated (for severe renal impairment, movement disorders); Not recommended (for pediatric use, breastfeeding); Caution (for moderate renal impairment, patients > 75 years).
• Eligibility-context constraints (as defined in official documents): The occurrence of movement disorders must lead to the definitive withdrawal of the medicine.

---

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use Setal MR by establishing an approved population (adults) and implementing absolute prohibitions based on pre-existing neurological conditions and severe kidney failure, alongside specific restrictions for age, moderate kidney impairment, and reproductive status.

The official regulatory profile for Setal MR (Trimetazidine Dihydrochloride) is characterized by a limited interaction liability with other medicinal products and substances. Regulatory labeling explicitly states that no formal drug interactions have been identified in studies involving co-administered medicines.

This low interaction risk is supported by the drug's metabolic profile. Official data confirms that Trimetazidine is neither an inhibitor nor an inducer of major drug-metabolizing enzymes, such as the Cytochrome P450 (CYP) system. This finding confirms the negligible risk of exposure-modifying interactions and the absence of documented contraindicated combinations or mandatory timing separation rules with other medicines. Furthermore, the drug’s exposure is formally documented as being not influenced by meals, and there are no specific warnings about interactions with alcohol, herbal products, or supplements in the regulatory interaction section.

The primary constraint related to the drug’s clearance involves specific patient populations, which results in a pharmacokinetic increase in plasma exposure. This increased exposure is officially noted in patients with moderate renal impairment (creatinine clearance between 30-60 mL/min) and in elderly patients over 75 years old due to age-related decrease in renal function. This population-specific clearance profile is the only documented consideration that alters the drug's exposure structure.

The mechanism of action for Setal MR (Trimetazidine Dihydrochloride) is characterized by its function as a cytoprotective metabolic agent that modulates energy generation within the heart muscle cell, or cardiomyocyte. The action is entirely cellular, resulting in a haemodynamically neutral physiological state.

Enzymatic Inhibition and Metabolic Re-programming

The core mechanism involves the selective enzymatic inhibition of Long-Chain 3-Ketoacyl Coenzyme A Thiolase (LC 3-KAT), an enzyme within the mitochondrial matrix. This molecular interaction slows the fatty acid beta-oxidation pathway, promoting a metabolic shift towards the more oxygen-efficient glucose oxidation. This re-programming results in the generation of energy (ATP) at a lower oxygen requirement by the heart muscle, modifying the cellular response to low-oxygen conditions.

Cytoprotection and Ion Homeostasis Stabilization

The metabolic shift limits the production of acidic byproducts, modulating the onset of intracellular acidosis during oxygen deprivation. This stability is crucial as it blocks the activation of ion exchangers that would otherwise lead to an uncontrolled influx of sodium (Na^+) and, subsequently, calcium (Ca^2+) inside the cell. Stabilization of ion homeostasis supports the maintenance of structural and functional integrity of the cardiomyocyte membranes, contributing to the preservation of cellular integrity during periods of oxygen scarcity.

How to Use Setal MR: Official Administration Guidelines

Setal MR (Trimetazidine Dihydrochloride Modified-Release) is administered via the oral route as a modified-release tablet. This formulation is designed for sustained delivery, meaning the tablet must be swallowed whole and must not be crushed, chewed, or split.

---

Standard Dosing and Frequency

The standard adult regimen for the 35 mg Modified-Release form is one tablet (35 mg) taken twice daily, once in the morning and once in the evening. This ensures a total daily intake of 70 mg. To facilitate consistent absorption, the administration of Setal MR is officially instructed to occur during meals.

---

Population-Specific Adjustments

Official prescribing information includes specific procedural rules for patients with reduced kidney function. For adults diagnosed with moderate renal impairment (creatinine clearance 30–60 mL/min), the dose must be reduced to one 35 mg tablet taken once daily in the morning. Usage in patients with severe renal impairment is restricted, and the medicine is generally not recommended for the pediatric population (under 18 years) as efficacy and safety have not been established in this group.

---

Instructions for Missed Doses

If a dose is missed, the recommended procedure is to take the next dose at the regularly scheduled time. It is an explicit instruction that a double dose must not be taken to make up for the missed one. The clinical benefit of treatment should typically be re-assessed after three months of use, and discontinued if no adequate response is observed.

Research evidence / Overview of studies for Setal MR

Evidence for Symptomatic Support in Stable Angina

Clinical research exploring Setal MR was studied for use in adults with stable angina pectoris, particularly when symptoms persist despite standard treatment. These investigations include multiple short-term, randomized controlled trials (RCTs), comparative studies, and large-scale, prospective observational studies used in research contexts involving fluctuating or unstable symptoms. Meta-analyses were also conducted to systematically review the trial data. Researchers conducted these trials to explore how symptoms change over defined time intervals when the medicine is added to a patient’s existing treatment plan.

The studies monitored outcomes reflecting daily functioning or activity level, specifically measuring outcomes describing episodic or acute changes and outcomes related to systemic or functional imbalance. Trials also monitored outcomes linked to physiological strain by assessing exercise tolerance and capacity parameters, such as the total time a person could exercise before experiencing signs of ischemia. These short-term studies monitored how symptoms varied in the observed populations. Some research highlights changes measured during the study period concerning patient-reported outcomes describing perceived discomfort and quality of life.

Outcomes Measured in Clinical Trials

Research protocols were applied in studies examining patient-reported outcomes describing perceived discomfort and functional limitations. The core research explored outcomes related to systemic or functional imbalance by looking at measures of ischemia, such as the time it took for certain changes to appear on an electrocardiogram (ECG) during stress testing. This approach provided insight into temporary physiological imbalance.

Findings describe patterns observed in the studies related to outcomes describing episodic or acute changes. In some short-term research exploring symptom changes, studies monitored how the severity of a patient's angina, as categorized by physician and patient reports, was observed in the study period. Research contributes to the broader evidence landscape. Study results reflect the specific conditions under which they were conducted.

Research in Specific Patient Groups

Setal MR was evaluated in studies focused on specific patient populations, including the elderly sub-population with stable angina. Furthermore, research was evaluated in patient groups with coexisting Type 2 Diabetes Mellitus. Studies monitored responses over defined time intervals.

Other dedicated research also examined patients with stable angina who had a history of a Myocardial Infarction (heart attack). These studies focused on outcomes reflecting daily functioning or activity level in these specific groups. However, it is important to note that results apply only to the populations studied, and data for certain groups remain insufficient.

Extended-Duration Studies and Follow-up

The clinical research was studied for varying time intervals. Many of the core randomized trials assessed primary symptomatic outcomes over short-term follow-up durations, typically ranging from 4 to 12 weeks. Intermediate follow-up periods, often extending up to 6 months, were used in some observational research to examine adherence and patterns observed in the studies.

Dedicated studies have explored the research scenarios related to major adverse cardiovascular events (MACE) and mortality over extended periods, with some follow-up lasting up to 5 years. However, long-term effects are not fully established. Research is ongoing.

Areas of Research Uncertainty and Gaps

The available research provides context but not individual predictions, and certainty remains low regarding certain aspects of Setal MR. A key research limitation is that comparative evidence is lacking in some areas. Direct head-to-head trials against all established anti-anginal drugs are not extensive.

Furthermore, several older studies that contributed to the initial evidence base were observed to have certain methodological weaknesses, according to regulatory analysis. Studies contribute to the broader evidence landscape. Evidence quality varies across studies. Finally, there is limited information for long-term outcomes that reflect major health events or mortality. The available research generally focuses on outcomes related to physical discomfort and functional measures.

Key Studies & References

1. Trimetazidine in Stable Angina (TRIMPOL II): A Randomized, Double-blind, Placebo-controlled Study

Common questions about Setal MR (FAQ)

Q: Is Setal MR the same as regular Setal tablets?

A: No, Setal MR is the modified-release form of the medicine (Trimetazidine), which is specifically designed for a sustained delivery of the drug over an extended period. The regular tablets are typically the immediate-release formulation, which has a shorter effect duration and different release characteristics. Official information notes the MR formulation has a prolonged therapeutic profile.

Q: Can Setal MR cause changes in mood or sleep?

A: Official regulatory documents have reported adverse reactions related to the nervous system, including sleep disorders. These effects may involve difficulty in sleeping (insomnia) or drowsiness. These effects are listed with an unknown frequency in the product information.

Q: What are the most commonly reported side effects of Setal MR?

A: According to official regulatory classifications, the most frequently reported side effects (common, affecting up to 1 in 10 users) include dizziness, headache, and various gastrointestinal issues such as nausea, vomiting, abdominal pain, indigestion, and diarrhea. A general feeling of weakness (asthenia), rash, and itching are also included in this frequency classification.

Q: Is it common to feel stomach upset when first starting Setal MR?

A: Gastrointestinal issues such as abdominal pain, nausea, vomiting, diarrhea, and indigestion are listed in official documents as common side effects. The official 'common' classification describes effects reported in up to 1 in 10 users. Official regulatory information, however, does not specify whether they are more or less common when treatment is first started.

Q: How quickly should someone expect to notice the effects of Setal MR?

A: Official regulatory data on the medicine’s absorption indicates that the maximum concentration in the bloodstream is reached on average 5 hours after taking the tablet. The medicine’s steady state, the point of consistent drug concentration, is generally reached by the 60th hour of treatment.

Q: How long does one dose of Setal MR typically last?

A: Regulatory documents state that the average elimination half-life of the medicine in healthy adults is between 7 and 12 hours. This means it takes this long for half the drug to be processed by the body. For the modified-release form, the plasma concentration is documented to stay at a sustained level for up to 11 hours.

Q: Can Setal MR be taken with common over-the-counter pain relievers?

A: According to the official product information, no formal drug interactions have been identified in studies involving co-administered medicines, including those commonly available over the counter. The medicine is documented as having a low interaction liability.

Q: Is it possible to take Setal MR with antacids or heartburn medication?

A: Official regulatory documentation states that no formal drug interactions have been identified between Trimetazidine and other medicinal products. The low liability suggests that taking it with these medications is not expected to pose a risk of interaction.

Q: Is Setal MR considered a controlled substance or addictive?

A: Setal MR is officially classified as an anti-anginal metabolic agent (ATC code C01EB15) based on its primary therapeutic use. Official regulatory information does not contain statements regarding the medicine's potential for abuse or addiction.

Q: Is Setal MR available for people who have liver disease?

A: While the official prescribing information does not list general liver disease as a contraindication, it does note a specific serious adverse reaction: Hepatitis (a liver disease) has been reported with an unknown frequency. The official documentation only lists severe renal impairment (kidney failure) as a specific organ-related contraindication.

Q: What is the function of the coating on the Setal MR tablet?

A: The coating is an essential part of the modified-release (MR) formulation. Its function is to allow for the controlled and sustained absorption of the medicine after administration. This ensures the drug is released slowly and in a sustained manner.

Q: Are there specific warnings about driving or operating machinery while on Setal MR?

A: Yes, official documents include a warning that the medicine may cause dizziness and drowsiness. Because these effects may affect the ability to drive or use machinery, official guidance suggests that individuals should be aware of their personal reaction to the medicine before performing such activities.

Q: What are the restrictions on alcohol consumption while taking Setal MR?

A: Official regulatory documents state that there are no specific warnings about interactions with alcohol in the core prescribing information. The official product documents do not include specific restrictions related to alcohol consumption in the interaction section.

Q: Can Setal MR be taken on an empty stomach?

A: Official instructions specify that Setal MR should be taken during meals. However, regulatory documents also note that the pharmacokinetic characteristics (how the drug is absorbed and distributed) are not influenced by meals. The instruction is provided to facilitate consistent use.

Q: What is the meaning of a 'pharmacovigilance' report related to Setal MR?

A: Pharmacovigilance is the official process related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. A report is an official submission detailing a suspected side effect that occurs after the medicine has been authorized and marketed.

Q: How is the safety of Setal MR monitored after it is approved?

A: The safety of the medicine is continuously monitored after approval through pharmacovigilance activities. This official process involves the collection and scientific assessment of reports concerning any suspected adverse drug reactions submitted by patients and healthcare professionals.

Q: What should be done if an allergic reaction is suspected while taking Setal MR?

A: Official patient information documents instruct the user that if an allergic reaction or a serious skin reaction is suspected, they should stop taking the medicine immediately. The patient information instructs seeking immediate medical attention as a procedural step for such a reaction.

Q: How long after stopping Setal MR does the medicine stay in the body?

A: The average elimination half-life of the medicine in healthy adults is reported in regulatory documents to be between 7 and 12 hours. The medicine will be virtually eliminated from the body after approximately five half-lives.

Q: Can Setal MR cause dry mouth?

A: Yes, official regulatory documents list dry mouth as an adverse effect that has been reported with the use of the medicine. However, the specific frequency of this reported effect is not officially classified in the core prescribing information.

Q: Do regulatory agencies classify Setal MR as a high-risk medication?

A: Official regulatory bodies classify the medicine based on its therapeutic use as an anti-anginal metabolic agent. The classification documents list specific contraindications (prohibitions) for patients with conditions like Parkinson's disease and severe renal impairment, rather than classifying the drug by a general 'high-risk' term.

Q: Where can I find the official prescribing information for Setal MR?

A: The official prescribing information is contained in documents such as the Summary of Product Characteristics (SmPC) for healthcare professionals and the Patient Information Leaflet (PIL) for the patient. These are made publicly available on the websites of national health agencies like the EMA, FDA, and MHRA.

Q: Is there a patient information leaflet (PIL) available online for Setal MR?

A: Yes, the Patient Information Leaflet (PIL) is a regulatory document that is typically made available online. It contains patient-specific information regarding the medicine's use, safety profile, and warnings, and can usually be found on the websites of the national regulatory agency that authorized the drug.

Q: What common supplements might interact with Setal MR?

A: Official regulatory documents state that no specific warnings about interactions with herbal products or supplements are present in the core prescribing information. This information is consistent with the drug's documented low interaction liability.

Q: Are there studies comparing the modified release to the immediate release version of Setal?

A: Research has been conducted to compare the bioavailability (how much drug reaches the bloodstream) of the modified-release formulation to the immediate-release tablet. One study described an improvement in bioavailability with the extended-release form.

Q: Does Setal MR need to be taken at a specific time of day?

A: Official regulatory guidance specifies that the medicine is to be taken twice daily, specifically once in the morning and once in the evening. This schedule is designed to help maintain a sustained concentration of the medicine over a 24-hour period.

How to Store and Dispose of Setal MR?

The storage and disposal of Setal MR (Trimetazidine Dihydrochloride Modified-Release Tablets) must adhere strictly to the conditions specified in official regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store at temperatures not exceeding 30°C.
Container	Keep in the original container (blister and carton) for protection.
Child Safety	Keep out of the sight and reach of children.
Stability	Do not use after the expiry date printed on the packaging.

Disposal Instructions

Unused or expired Setal MR must be handled as pharmaceutical waste. Do not dispose of this medicine via wastewater or household waste. It must be discarded in accordance with local requirements, which usually involves returning the product to a pharmacist or a designated collection scheme.